Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 23:19:1723-1748.
doi: 10.2147/IJN.S451206. eCollection 2024.

Natural Products-Based Inhaled Formulations for Treating Pulmonary Diseases

Jiangyan Yong #  1 , Hongli Shu #  1 , Xiao Zhang #  2 , Kun Yang  3 , Guining Luo  3 , Lu Yu  3 , Jiaqi Li  3 , Hong Huang  4
Affiliations
Review

Natural Products-Based Inhaled Formulations for Treating Pulmonary Diseases

Jiangyan Yong et al. Int J Nanomedicine. .

Abstract

Given the unique physiological and pathological characteristics of the lung, the direct, inhalable route is more conducive to pulmonary drug delivery and disease control than traditional systemic drug delivery, significantly circumventing drug loss, off-target effects, systemic and organ toxicity, etc., and is widely regarded as the preferred regimen for pulmonary drug delivery. However, very few lung diseases are currently treated with the preferred inhaled formulations, such as asthma, chronic obstructive pulmonary disease and pulmonary hypertension. And there is a lack of appropriate inhaled formulations for other critical lung diseases, such as lung cancer and pulmonary fibrosis, due to the fact that the physicochemical properties of the drugs and their pharmacokinetic profiles do not match the physiology of the lung, and conventional inhalation devices are unable to deliver them to the specific parts of the lung. Phytochemicals of natural origin, due to their wide availability and clear safety profile, hold great promise for the preparation of inhalable formulations to improve the current dilemma in the treatment of lung diseases. In particular, the preparation of inhalable formulations based on nano- and microparticulate carriers for drug delivery to deep lung tissues, which overcome the shortcomings of conventional inhalation therapies while targeting the drug activity directly to a specific part of the lung, may be the best approach to change the current dilemma of lung disease treatment. In this review, we discuss recent advances in nano- and micron-carrier-based inhalation formulations for the delivery of natural products for the treatment of pulmonary diseases, which may represent an opportunity for practical clinical translation of natural products.

Keywords: inhalation therapy; inhaled nanoformulations; nanomedicine; natural products; pulmonary diseases.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Benefits of natural product-based inhaled nanoformulations in the treatment of pulmonary diseases.
Figure 2
Figure 2
Drug delivery nano/micron carriers for natural products.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Soriano JB, Kendrick PJ, Paulson KR. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596. doi:10.1016/S2213-2600(20)30105-3 - DOI - PMC - PubMed
    1. Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20(9):624–639. doi:10.1038/s41571-023-00798-3 - DOI - PubMed
    1. Bai X, Zhao G, Chen Q, et al. Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge. Sci Adv. 2022;8(25):eabn7162. doi:10.1126/sciadv.abn7162 - DOI - PMC - PubMed
    1. Shen AM, Minko T. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery. J Control Release. 2020;326:222–244. doi:10.1016/j.jconrel.2020.07.011 - DOI - PMC - PubMed
    1. Mehta P, Bothiraja C, Mahadik K, et al. Phytoconstituent based dry powder inhalers as biomedicine for the management of pulmonary diseases. Biomed Pharmacother. 2018;108:828–837. doi:10.1016/j.biopha.2018.09.094 - DOI - PubMed

Substances